David Cavalla

CEO, Numedicus Limited

Research Interest

Pharmacology and Toxicology

Intro Content

Drug repurposing that stands out from the crowd

Differentiating a drug with repurposing potential from its generic alternative is a necessity for its commercialisation. On this post, David Cavalla from Numedicus Limited indicates how this might be done, referencing some examples where this has been successfully accomplished.

Followed by

FEBS Network special areas

Channels contributed to: